SecBot SecBot
8-K ·Filed Nov 3, 2026

PFE

PFIZER INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed13d 4h ago SEC0000078003-26-000132
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor Pfizer's upcoming quarterly earnings for any changes in financial strategy or capital allocation under the permanent CFO. No immediate trading catalyst from this appointment.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$30.79
T+0 close · Nov 3, 2026 · via day close
Latest settled
−4.35%
T+5 · $29.45 · next T+20 in 16d
Vs SPY
−3.44%
α at T+5
Latest observation
−3.96%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $30.79entry
  2. T+1 · 12d ago −2.96%α +1.45% · $29.88
  3. T+5 · 6d ago −4.35%α −3.44% · $29.45
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pfizer announced the permanent appointment of Cecile Guegan as CFO and Executive Vice President, effective November 1, 2026, after she served as interim CFO since August 2026. The filing includes her compensation package: $1.3M base salary and $1.3M target cash incentive. This is a routine succession event with no material financial impact.

Key Facts

  • Cecile Guegan elected CFO and Executive Vice President effective November 1, 2026
  • She had served as interim CFO since August 16, 2026
  • Annual base salary of $1,300,000
  • Annual target cash incentive opportunity of $1,300,000 (100% of base salary)
  • Guegan has over 25 years of pharmaceutical finance experience, joined Pfizer via 2009 Wyeth acquisition

Financial Impact

Compensation package of $2.6M annual total (base + target cash incentive) for a $170.7B market cap company; no material financial impact

Risk Factors

  • No material risks identified; this is a routine executive appointment

Market Snapshot

Price
$30.07
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
38% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000078003-26-000132
Document: pfizerappointscecileguegan.htm0000078003-26-000132
Document: 0000078003-26-000132-index-headers.html0000078003-26-000132
Document: 0000078003-26-000132-index.html0000078003-26-000132
Document: 0000078003-26-000132.txt0000078003-26-000132

Track record

21 reports on PFE

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Viewing Entry $30.79 Now $28.89 −6.17% settles Feb 2
  2. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.89 −3.70% settles Feb 1
  3. Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.89 −5.80% settles Jan 29
  4. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.89 −3.80% settles Jan 21
  5. Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.89 +7.84% ▲ +9.11% +12.15% vs SPY
  6. Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
  7. Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
  8. Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
  9. Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
  10. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026